Knight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan sold 300,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of C$6.13, for a total transaction of C$1,839,000.00.
Knight Therapeutics Stock Performance
Shares of Knight Therapeutics stock opened at C$6.02 on Friday. The stock's fifty day simple moving average is C$5.72 and its 200 day simple moving average is C$5.69. The company has a current ratio of 3.41, a quick ratio of 1.79 and a debt-to-equity ratio of 7.62. The company has a market capitalization of C$609.28 million, a PE ratio of -30.10, a PEG ratio of -1,013.50 and a beta of 0.48. Knight Therapeutics Inc. has a 12 month low of C$4.35 and a 12 month high of C$6.23.
Knight Therapeutics (TSE:GUD - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported C($0.02) EPS for the quarter, missing analysts' consensus estimates of C$0.03 by C($0.05). Knight Therapeutics had a negative return on equity of 2.70% and a negative net margin of 6.28%. The business had revenue of C$95.57 million for the quarter, compared to analyst estimates of C$89.83 million. On average, research analysts predict that Knight Therapeutics Inc. will post 0.1077501 EPS for the current year.
Analysts Set New Price Targets
Bill Gates’s Next Big AI Bet: Stargate
From Brownstone Research | Ad
In February 2016… when almost nobody was talking about artificial intelligence….
I picked Nvidia as one of my favorite stocks.
Shares have jumped by more than 20,000% since then.
I believe we are about to do it again with this new AI project called Stargate
Several brokerages have commented on GUD. Stifel Nicolaus upgraded shares of Knight Therapeutics from a "hold" rating to a "buy" rating and upped their target price for the company from C$5.75 to C$6.75 in a research report on Tuesday, August 13th. Stifel Canada upgraded Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Monday, August 12th.
Read Our Latest Stock Analysis on Knight Therapeutics
Knight Therapeutics Company Profile
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
